Monday, April 17
Partin B
Focus Group | Beigene Overview and BRUKINSA® (zanubrutinib) Clinical Update
8:00 AM - 9:15 AM
This presentation is designed to provide the audience with a brief introduction to BeiGene and its pipeline with a focus on the clinical development of zanubrutinib (Brukinsa ®), a bruton’s tyrosine kinase inhibitor. This discussion is intended to be interactive in order to gain insights on clinical trial development (eg, head-to-head) and how compendia incorporation may impact decision-making for treatment.
Focus Group | Beigene Overview and BRUKINSA® (zanubrutinib) Clinical Update
9:30 AM - 10:45 AM
This presentation is designed to provide the audience with a brief introduction to BeiGene and its pipeline with a focus on the clinical development of zanubrutinib (Brukinsa ®), a bruton’s tyrosine kinase inhibitor. This discussion is intended to be interactive in order to gain insights on clinical trial development (eg, head-to-head) and how compendia incorporation may impact decision-making for treatment.
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 8,500+ employees around the world are committed to expediting the development of a diverse pipeline of novel therapeutics.
Address: 1840 Gateway Drive 3rd Floor, San Mateo, CA 94404
Contact Phone Number: 877-828-5568
Contact Email: Torry Thomas